📣 VC round data is live. Check it out!

Bionano Genomics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Bionano Genomics and similar public comparables like Arcoma, Clinical Laserthermia, Boule Diagnostics, Observe Medical and more.

Bionano Genomics Overview

About Bionano Genomics

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.


Founded

2007

HQ

United States

Employees

100

Financials (LTM)

Revenue: $30M
Net Income: ($28M)

EV

$17M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Bionano Genomics Financials

Bionano Genomics reported last 12-month revenue of $30M.

In the same LTM period, Bionano Genomics generated $14M in gross profit and had net loss of ($28M).

Revenue (LTM)


Bionano Genomics P&L

In the most recent fiscal year, Bionano Genomics reported revenue of $29M and EBITDA of ($16M).

Bionano Genomics is unprofitable as of last fiscal year, with gross margin of 46%, EBITDA margin of (57%), and net margin of (93%).

See analyst estimates for Bionano Genomics
LTMLast FY202320242025202620272028
Revenue$30M$29M$36M$31M$29M
Gross Profit$14M$13M$10M$380K$13M
Gross Margin47%46%26%1%46%
EBITDA($16M)($213M)($95M)($16M)
EBITDA Margin(57%)(591%)(310%)(57%)
EBIT Margin(108%)(117%)(382%)(248%)(117%)
Net Profit($28M)($26M)($232M)($112M)($26M)
Net Margin(94%)(93%)(644%)(364%)(93%)

Financial data powered by Morningstar, Inc.

Bionano Genomics Stock Performance

Bionano Genomics has current market cap of $14M, and enterprise value of $17M.

Market Cap Evolution


Bionano Genomics' stock price is $1.25.

Bionano Genomics share price increased by 7.3% in the last 30 days, and decreased by 65.9% in the last year.

Bionano Genomics has an EPS (earnings per share) of $-2.30.

See more trading valuation data for Bionano Genomics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$17M$14M0.8%7.3%8.7%-65.9%$-2.30

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Bionano Genomics Valuation Multiples

Bionano Genomics trades at 0.6x EV/Revenue multiple, and (1.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for Bionano Genomics

EV / Revenue (LTM)


Bionano Genomics Financial Valuation Multiples

As of May 23, 2026, Bionano Genomics has market cap of $14M and EV of $17M.

Bionano Genomics has a P/E ratio of (0.5x).

LTMLast FY202320242025202620272028
EV/Revenue0.6x0.6x0.5x0.6x0.6x
EV/EBITDA(1.0x)(0.1x)(0.2x)(1.0x)
EV/EBIT(0.5x)(0.5x)(0.1x)(0.2x)(0.5x)
EV/Gross Profit1.2x1.3x1.8x44.6x1.3x
P/E(0.5x)(0.5x)(0.1x)(0.1x)(0.5x)
EV/FCF(1.0x)(0.1x)(0.2x)(1.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Bionano Genomics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Bionano Genomics Margins & Growth Rates

Bionano Genomics grew revenue by 13% and net profit by 16% in the last fiscal year.

In the most recent fiscal year, Bionano Genomics reported gross margin of 46%, EBITDA margin of (57%), and net margin of (93%).

See estimated margins and future growth rates for Bionano Genomics

Bionano Genomics Margins

Last FY202420252026202720282029
Gross Margin46%1%46%49%
EBITDA Margin(57%)(310%)(57%)
EBIT Margin(117%)(248%)(117%)(97%)
Net Margin(93%)(364%)(93%)(95%)
FCF Margin(57%)(224%)(57%)

Bionano Genomics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth13%(15%)(7%)13%
Gross Profit Growth19%(96%)3370%19%
EBITDA Growth(55%)(83%)
EBIT Growth(7%)(45%)(56%)(7%)
Net Profit Growth16%(52%)(76%)16%
FCF Growth(46%)(76%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Bionano Genomics Operational KPIs

Bionano Genomics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.

Access forward-looking KPIs for Bionano Genomics
LTMLast FY202320242025202620272028
Revenue per Employee$0.3M
Opex per Employee$0.5M
R&D Expenses to Revenue38%40%150%81%40%
Opex to Revenue163%408%249%163%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Bionano Genomics Competitors

Bionano Genomics competitors include Arcoma, Clinical Laserthermia, Boule Diagnostics, Observe Medical, Conneqt Health, ViroGates, Advanced Medical, Scandinavian Real Heart, Labo Euromedis and Scandinavian Medical.

Most Bionano Genomics public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Arcoma0.8x0.8x7.5x7.1x
Clinical Laserthermia6.8x5.3x(4.5x)(4.7x)
Boule Diagnostics0.7x0.7x7.5x8.9x
Observe Medical8.6x(5.4x)
Conneqt Health6.8x7.4x(1.4x)
ViroGates9.3x(8.0x)
Advanced Medical64356.9x3799.8x
Scandinavian Real Heart(3.9x)

This data is available for Pro users. Sign up to see all Bionano Genomics competitors and their valuation data.

Start Free Trial

Bionano Genomics Funding History

Before going public, Bionano Genomics raised $120M in total equity funding, across 5 rounds.


Bionano Genomics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Aug-16Series DDomain Associates; LC Ventures; Novartis Venture Fund$32M
Mar-16Series DDomain Associates; Legend Capital; Novartis Venture Fund$10M
Feb-15Series C$15MBionano Genomics completed a $53 million Series C financing round in November 2014, with a follow-on Series C-II in January/February 2015. Investors included Novartis Venture Fund, Federated Kaufmann Fund, Monashee Investment Management, Legend Capital, Domain Associates, Battelle Ventures, and Gund Investment Corporation. Darren Cai from Legend Capital and Campbell Murray from Novartis Venture Fund joined the board. The funds supported commercialization of the Irys platform for genome mapping, detection of structural variations, development of next-generation platforms, and technology innovations. The Irys system addresses structural variations like insertions, deletions, inversions, translocations, and repeats, often missed by other genomics tools, positioning it for personalized medicine and diagnostics.
Nov-14Series CBattelle Ventures; Domain Associates; Gund Investment, LLC; Legend Capital; Novartis Venture Fund$53MBionano Genomics, originally founded in 2008 as BioNanomatrix, develops genome mapping technology to detect long-range genomic information for applications like cancer treatment. The company closed a $53 million Series C funding round on November 20, 2014, co-led by Legend Capital and Novartis Venture Fund, with participation from Battelle Ventures, Domain Associates, Gund Investment Corporation, Federated Kaufmann Fund, and Monashee Investment Management. This round brought total funding to approximately $113 million in debt and equity. Legend Capital executive director Darren Cai and Novartis Venture Fund managing director Campbell Murray joined the board. Proceeds from the Series C were allocated to accelerate commercialization of the Irys platform and initiate development of next-generation platforms. Past investors included KT Venture Group, the corporate venturing arm of KLA-Tencor.
Oct-13Series CBattelle Ventures; Domain Associates; Gund Investment, LLC$10MBioNano Genomics raised $10 million in financing on October 2, 2013, from existing investors Battelle Ventures, Domain Associates, and Gund Investment Corporation to support development and commercialization of the Irys system for human genome analysis. The Irys system enables direct observation of native genomic structure through imaging of long molecules, detecting structural variation, improving genome assemblies, and phasing haplotypes, with scalability demonstrated for large genomes like human. The funding aimed to expand commercialization efforts in the U.S., China, and Europe for biomedical disease research and diagnostic development in genomics and epigenomics.

Bionano Genomics M&A Activity

Bionano Genomics has acquired 3 companies to date.

Last acquisition by Bionano Genomics was on November 28th 2022. Bionano Genomics acquired Purigen Biosystems for $64M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Bionano Genomics

Purigen Biosystems
BioDiscovery
Lineagen
Description
Purigen Biosystems is a Pleasanton-based biotechnology firm specializing in nucleic acid purification using isotachophoresis technology. The Ionic Purification System processes DNA and RNA from challenging samples like FFPE tissues and low-input cells without surface binding, yielding high-quality extracts for next-generation sequencing. Adopted by academic labs and pharma researchers worldwide, the platform launched commercially in 2020 following Series A funding.
BioDiscovery is an El Segundo, California-based scientific software provider for genomic analysis and genetic research. Its NGI software suite supports NGS data visualization, CNV detection, and structural variant calling for array and sequencing platforms. Used by over 1,000 labs worldwide, including NIH-funded projects, the tools integrate with Illumina and Affymetrix systems. Established in 2007, BioDiscovery also offers consulting for cytogenetics workflows.
Lineagen is a molecular diagnostics company specializing in genetic testing for neurodevelopmental disorders like autism spectrum disorder, multiple sclerosis, and chronic obstructive pulmonary disease. Salt Lake City-headquartered, it leverages the University of Utah's Population Database to identify biomarkers and develop tests such as the INFINITEST array for early childhood screening. Founded in 2002, Lineagen offers comprehensive genetic counseling alongside its assays, aiding clinicians in personalized treatment plans. The company commercializes proprietary research into diagnostic panels targeting complex diseases influenced by genetics.
HQ CountryUnited StatesUnited StatesUnited States
HQ City
San Francisco, CA
Ann Arbor, MI
Salt Lake City, UT
Deal Date28 Nov 202212 Oct 202124 Aug 2020
Valuation$64M$100M$10M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Bionano Genomics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Bionano Genomics

When was Bionano Genomics founded?Bionano Genomics was founded in 2007.
Where is Bionano Genomics headquartered?Bionano Genomics is headquartered in United States.
How many employees does Bionano Genomics have?As of today, Bionano Genomics has over 100 employees.
Who is the CEO of Bionano Genomics?Bionano Genomics' CEO is R. Erik Holmlin.
Is Bionano Genomics publicly listed?Yes, Bionano Genomics is a public company listed on Nasdaq.
What is the stock symbol of Bionano Genomics?Bionano Genomics trades under BNGO ticker.
When did Bionano Genomics go public?Bionano Genomics went public in 2018.
Who are competitors of Bionano Genomics?Bionano Genomics main competitors include Arcoma, Clinical Laserthermia, Boule Diagnostics, Observe Medical, Conneqt Health, ViroGates, Advanced Medical, Scandinavian Real Heart, Labo Euromedis, Scandinavian Medical.
What is the current market cap of Bionano Genomics?Bionano Genomics' current market cap is $14M.
What is the current revenue of Bionano Genomics?Bionano Genomics' last 12 months revenue is $30M.
What is the current revenue growth of Bionano Genomics?Bionano Genomics revenue growth (NTM/LTM) is 22%.
What is the current EV/Revenue multiple of Bionano Genomics?Current revenue multiple of Bionano Genomics is 0.6x.
Is Bionano Genomics profitable?No, Bionano Genomics is not profitable.
What is the current net income of Bionano Genomics?Bionano Genomics' last 12 months net income is ($28M).
How many companies Bionano Genomics has acquired to date?As of May 2026, Bionano Genomics has acquired 3 companies.
What was the largest acquisition by Bionano Genomics?$100M acquisition of BioDiscovery on 12th October 2021 was the largest M&A Bionano Genomics has done to date.
What companies Bionano Genomics acquired?Bionano Genomics acquired BioDiscovery, Purigen Biosystems, and Lineagen.
In how many companies Bionano Genomics has invested to date?Bionano Genomics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Bionano Genomics

Lists including Bionano Genomics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial